Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.

Cha, Seung E; Kujawski, Maciej; J Yazaki, Paul; Brown, Christine; Shively, John E

Cha, Seung E; Kujawski, Maciej; J Yazaki, Paul; Brown, Christine; Shively, John E.

Afiliación

Cha SE; Department of Immunology and Theranostics, City of Hope, Duarte, USA.
Kujawski M; Irell & Manella Graduate School of Biological Sciences, City of Hope, Duarte, USA.
J Yazaki P; Department of Immunology and Theranostics, City of Hope, Duarte, USA.
Brown C; Department of Immunology and Theranostics, City of Hope, Duarte, USA.
Shively JE; Irell & Manella Graduate School of Biological Sciences, City of Hope, Duarte, USA.

Oncoimmunology ; 10(1): 1899469, 2021 03 18.

Article en En | MEDLINE | ID: mdl-33796409

Asunto(s)

Inmunoterapia Adoptiva; Neoplasias; Receptores Quiméricos de Antígenos; Animales; Antígeno Carcinoembrionario/genética; Interleucina-2; Ratones; Neoplasias/terapia; Linfocitos T

Palabras clave

CEA transgenic mice; Carcinoembryonic antigen (CEA); chimeric antigen receptor T cells (CAR T); immunocytokine; lymphodepletion; tumor immunity

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Receptores Quiméricos de Antígenos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Oncoimmunology Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google